Beyond ovarian and breast cancer: Are PARP inhibitors finally proving their worth in urologic oncology?
The class of poly (ADP-ribose) polymerase inhibitors, once celebrated as a breakthrough in ovarian and breast cancer, has endured a reputation decline following safety concerns and regulatory rollbacks. But recent data suggest that prostate cancer, specifically metastatic castration-resistant prostate cancer with BRCA mutations, may offer PARP inhibitors a new lease on life. The December 2025 […]